Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7289MR)

This product GTTS-WQ7289MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7289MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12833MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ9558MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ13569MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ4485MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ1532MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ6999MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ8663MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ11035MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-128
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW